CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Determining your retirement savings goal at 30 is crucial for financial stability. Learn what you should aim for to secure your retirement.
25,114 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A leading toy company stunned traders with a strong earnings beat, triggering a rapid Friday rally. Learn the key fig...
Airbnb (ABNB) enters 2026 with evolving monetization and travel demand. This guide breaks down Q1 insights, margins, ...
Adobe's 2026 earnings trajectory hinges on subscription momentum, AI-enabled products, and disciplined costs. This gu...
The Meta deal lights up new questions about AMD's growth path and dilution risk. This guide breaks down what the 6 gi...
Investors are watching alarm.com with a focus on how 2026 earnings will unfold. This guide explains the key drivers, ...
A once unimaginable moment is explored: spacex surpassed broadcom, meta on IPO day. This piece breaks down what that ...
When Space Force makes obvious moves to pause launches from Boeing and Lockheed's space venture, investors face a tes...
As Progyny gears up for 2026, investors want clarity on what drives progyny (pgny) 2026 earnings. This guide breaks d...
As Rocket Lab broadens beyond launches into aerospace and defense, a renewed thesis supports a potential growth path ...
NASA issued a comprehensive review of Boeing's Starliner program, yet the agency has not pulled the plug. Here’s how ...
Nike's profit margins fell as the company faced pricing, demand, and currency headwinds. This guide breaks down the m...